# MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR

Study · id `cardio:ct-nct03705312` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03705312](<https://clinicaltrials.gov/study/NCT03705312>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03705312

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 174 participants.

## Technical summary

Registry record NCT03705312. Randomized; single masking; primary purpose treatment. Start 2019-02-22 (actual); primary completion 2021-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 174 participants (planned count; ClinicalTrials.gov record NCT03705312, source copy `cardio:ctgov-nct03705312-2019-08-14`, retrieved 2026-10-26)
- Started: 2019-02-22 (actual) (ClinicalTrials.gov record NCT03705312, source copy `cardio:ctgov-nct03705312-2019-08-14`, retrieved 2026-10-26)
- Primary completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03705312, source copy `cardio:ctgov-nct03705312-2019-08-14`, retrieved 2026-10-26)
- Completion: 2022-01 (anticipated) (ClinicalTrials.gov record NCT03705312, source copy `cardio:ctgov-nct03705312-2019-08-14`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03705312, source copy `cardio:ctgov-nct03705312-2019-08-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03705312-2019-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR
- Acronym: EVOLVE-MR
- Condition: Mitral Regurgitation
- Condition: Heart Failure
- Condition: Mitral Valve Regurgitation Due to Cardiomyopathy (Disorder)
- Intervention (Device): Transcatheter mitral valve repair
- Intervention (Other): Guideline-directed medical therapy
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER
- Collaborator: Abbott Medical Devices
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)
- Registry lists this organization as a collaborator: Abbott (`cardio:abbott`)

## Provenance

Content hash: 613acca208a752bc4b55d0ece9a387ffc6eebd26d63c4c2a72be53b2412d170b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
